Inappropriate Grading of Adverse Events in Cancer Clinical Trials—Reply

JAMA Oncology - United States
doi 10.1001/jamaoncol.2018.5871
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Medical Association (AMA)

Related search

A Review of Methods for Monitoring Adverse Events in Pediatric Psychopharmacology Clinical Trials

Drug Safety
ToxicologyPharmacology
2018English

Pcn368 - Concordance Between Patients and Clinicians’ Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: A Systematic Review

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Failure to Report Harms and Adverse Events in Clinical Trials: Why Does the Problem Continue?

Canadian Journal of Anaesthesia
MedicineAnesthesiologyPain Medicine
2012English

Physician-Reported Experience and Understanding of Adverse Event Attribution in Cancer Clinical Trials

Mayo Clinic Proceedings: Innovations, Quality & Outcomes
2019English

Clinical Management of Adverse Events Associated With Lorlatinib

Oncologist
Cancer ResearchMedicineOncology
2019English

Correction To: Serious Adverse Events and Fatal Adverse Events Associated With Nivolumab Treatment in Cancer Patients

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Delayed Adverse Events in Phase I Trials of Molecularly Targeted and Cytotoxic Agents

Oncotarget
Oncology
2018English

Adverse Events in Clinical Islet Transplantation: One Institutional Experience

Cell Transplantation
TransplantationBiomedical EngineeringCell Biology
2012English

Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia

JAMA Dermatology
DermatologyMedicine
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy